NovoCure Limited
(NVCR)
undefined
undefined%
At close: undefined
33.30
-0.06%
After-hours Dec 13, 2024, 07:55 PM EST
Company Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China.
Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma.
The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.
NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
NovoCure Limited
| Country | JE |
| IPO Date | Oct 1, 2015 |
| Industry | Medical - Instruments & Supplies |
| Sector | Healthcare |
| Employees | 1,453 |
| CEO | Asaf Danziger |
Contact Details
Address: No. 4 The Forum Saint Helier, JE | |
| Website | https://www.novocure.com |
Stock Details
| Ticker Symbol | NVCR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001645113 |
| CUSIP Number | G6674U108 |
| ISIN Number | JE00BYSS4X48 |
| Employer ID | 00-0000000 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Asaf Danziger | Chief Executive Officer & Director |
| Ashley Cordova | Chief Financial Officer |
| Mukund Paravasthu | Chief Operating Officer |
| Prof. Yoram Palti M.D., Ph.D. | Founder & Chief Technology Officer |
| Barak Ben Arye | General Counsel |
| Frank Leonard | Executive Vice President & President of Novocure Oncology |
| Ingrid Goldberg | Vice President of Investor Relations |
| Michael Puri | Chief Human Resources Officer |
| Uri Weinberg M.D., Ph.D. | Chief Innovation Officer |
| William F. Doyle | Executive Chairman |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 02, 2024 | 8-K | Current Report |
| Nov 06, 2024 | 4 | Filing |
| Nov 04, 2024 | 4 | Filing |
| Nov 04, 2024 | 4 | Filing |
| Nov 04, 2024 | 4 | Filing |
| Oct 30, 2024 | 8-K | Current Report |
| Oct 30, 2024 | 10-Q | Quarterly Report |
| Oct 15, 2024 | 8-K | Current Report |
| Oct 09, 2024 | 3 | Filing |
| Sep 03, 2024 | 8-K | Current Report |